An honest, side-by-side look at every major telehealth PrEP platform — what they cost, where they work, and what they actually cover.
| Provider | Cost to you | States | At-home labs | Uninsured? | Injectable PrEP | 340B model | |
|---|---|---|---|---|---|---|---|
|
Recommended MISTR |
$0 Insured & uninsured |
50 states + DC + PR | Yes | Yes — $0 | Enrolling for Yeztugo | Yes | Visit MISTR Code: ANDR735 |
| Q Care Plus | $0 99% of insured |
Eligible states | Yes | Limited | Not yet | Yes (CBO) | Visit |
| Freddie | $0 for most | 50 states | Yes | Yes | Coming soon | Not confirmed | Visit |
| Nurx | $15–$30 + labs | ~36 states | Yes | Higher cost | No | No | Visit |
| PlushCare | $99–$129 + membership | Most states | No (in-person) | Expensive | No | No | Visit |
| FOLX Health | Membership-based | 50 states | Via partner | Membership fee | No | No | Visit |
Truly $0 for insured and uninsured. Covers medication, labs, and consultations. 50-state coverage. 500,000+ patients served.
ConsBrand Descovy focus (340B economics). Injectable support still rolling out.
Helps keep FreePrEP.org running & connects more people with free PrEP.
Visit MISTRStrong CBO partnership model. High satisfaction rates.
ConsNot available in all states. Limited uninsured support.
50-state coverage. Supports uninsured patients.
Cons340B model not confirmed. No injectable PrEP yet.
Established brand. Broad service range beyond PrEP.
ConsConsultation fee. Lab fees for uninsured. Limited state coverage. No 340B model.
Full-service telehealth beyond PrEP. Insurance billing available.
ConsHigh consultation fee. Requires in-person labs. Membership model. Not PrEP-focused.
LGBTQ+-focused. Inclusive care model. Hormone therapy + PrEP under one roof.
ConsMembership-based pricing. No 340B model. Not the cheapest PrEP path.
Platforms like MISTR and Q Care Plus partner with 340B-eligible covered entities (FQHCs, Ryan White clinics). The covered entity purchases PrEP at the steep 340B discount but bills insurance at the standard rate. The spread — estimated at $900–$2,200 per Descovy prescription — funds the platform and subsidizes care for uninsured patients.
This is why 340B-based platforms overwhelmingly prescribe brand Descovy over generic TDF/FTC — the margin on brand drugs is much larger. This isn't necessarily bad (Descovy has fewer kidney and bone side effects), but it's worth understanding the economic incentive.
For most people, MISTR is the best starting point. They serve all 50 states, cover insured and uninsured patients at $0, include at-home labs and telehealth consultations, and have served over 500,000 patients. If MISTR doesn't serve your state or situation, Q Care Plus and Freddie are strong alternatives.
If cost isn't your primary concern and you want a full-service telehealth experience, Nurx and PlushCare are reputable options — but they're not free for most patients.
FOLX Health is worth considering if you're also receiving gender-affirming care and want everything under one provider.
Our eligibility tool asks about your insurance, state, and income, then recommends specific platforms based on your situation. Takes 60 seconds.
Answer a few quick questions and we'll match you with the platforms that fit your situation.
Start the Eligibility Tool